The variation of surface markers in DCs of patients with CC, CIN and controls To further characterize DCs in cancer patients, we next determined their expressions of the surface markers HLA-DR, CD80, and CD86 by flow cytometry. The expressions of these antigens are shown in Table 2 and Figure 3. We found the HLA-DR expression in the CIN group (48.09 ± 16.07%) was higher than that in the healthy individuals #Ferrostatin-1 ic50 randurls[1|1|,|CHEM1|]# (42.70 ± 17.53%) and highest in patients with cervical carcinoma (60.59 ± 14.64%). It was significantly higher (P < 0.05) in the CC group compared to the CIN group and the controls. But no significant

differences (P > 0.05) between the CIN groups and the controls were observed. Table 2 The functional immunophenotypings of DCs in patients selleck inhibitor with CC, CINII-III and controls   Normal (n = 62) CINII-III (n = 54) CC (n = 37) P HLA-DR 42.70 ± 17.53 48.09 ± 16.07 60.59 ± 14.64 0.082* 0.000** 0.001*** CD80 51.2 3 ± 17.16 49.52 ± 21.74 39.59 ± 17.39 0.633* 0.004** 0.017*** CD86 49.02 ± 21.58 46.92 ± 15.24 42.54 ± 19.51 0.803* 0.157** 0.111*** *Normal vs CINII~III; ** Normal vs CC; *** CINII~III vs CC P of the three groups: HLA-DR: P = 0.000, F = 13.634; CD80: P = 0.012, F = 4.587; CD86: P = 0.241, F = 1.438 Figure 3 The functional immunophenotypings of DCs in patients with CC, CIN and controls. We also detected the expression

of CD80 and CD86 on the surface of DCs. The expression of CD80 and CD86 in the CIN group (CD80: 49.52 ± 21.74%; CD86: 46.92 ± 15.24%) was lower than that of the healthy individuals (CD80: 51.23 ± 17.16%; CD86: 49.02 ± 21.58%), and lowest in patients with cervical carcinoma (CD80: 39.59 ± 17.39%; CD86: 42.54 ± 19.51%). There was significantly lower (P < 0.05) CD80 expression in the CC groups than in the controls, and also significantly lower expression (P < 0.05) in the CC group than in the CIN group. But no significant differences (P > 0.05) between the CIN groups and the controls were observed. There were no significant differences in CD86 between any groups. DCs from the peripheral blood of cancer patients thus exhibit decreased expression of these costimulatory molecules as compared to controls.

Cytokine secretion in CC, CIN and controls over We next investigated cytokine secretion in patients with CC and CIN compared to controls. The levels of these cytokines are shown in Table 3and Figure 4, Figure 5. Women with CIN (18.19 ± 12.58 pg/mL) had significantly higher IL-6 levels in their peripheral blood than did controls (11.29 ± 6.36 pg/mL); IL-6 levels were highest in women with CC (23.67 ± 11.36 pg/mL). There were significant differences between any two groups. Table 3 The serum cytokines secretion in patients with CC, CINII-III and controls   Normal (n = 62) CINII-III (n = 54) CC (n = 37) P IL-6 ( pg/ml) 11.29 ± 6.36 18.19 ± 12.58 23.67 ± 11.36 0.000* 0.000** 0.013*** TGFβ ( ng/ml ) 5.60 ± 4.83 6.41 ± 5.20 18.22 ± 12.18 0.598* 0.000** 0.000*** IL-10 ( pg/ml ) 52.69 ± 28.27 57.